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Abstract
Titin, the largest protein known, has attracted a lot of interest in the cardiovascular field in recent years, since the discovery 
that truncating variants in titin are commonly found in patients with dilated cardiomyopathy. This review will discuss the 
contribution of variants in titin to inherited cardiac conditions (cardiomyopathies) and how model systems, such as animals 
and cellular systems, can help to provide insights into underlying disease mechanisms. It will also give an outlook onto 
exciting technological developments, such as in the field of CRISPR, which may facilitate future research on titin variants 
and their contributions to cardiomyopathies.
Keywords Titin · Animal models · Induced pluripotent stem cell derived cardiomyocytes · CRISPR/Cas9 · Genome-
engineering · Cardiomyopathy
Abbreviations
CRISPR  Clustered regularly interspaced short palin-
dromic repeat
CRISPRa  CRISPR activation system
CRISPRi  CRISPR interference
DCM  Dilated cardiomyopathy
HCM  Hypertrophic cardiomyopathy
iPSC  Induced pluripotent stem cells
iPSC-CM  Induced pluripotent stem cell derived 
cardiomyocyte(s)
TTNtv  Titin truncating variant(s)
PSI  Percentage spliced in
RNAseq  RNA sequencing
Introduction
Titin, historically also known as connectin (Maruyama 
1976), is the largest protein known: with 3.4–3.9 megadal-
ton it is 100 times larger than an “ordinary protein”, e.g. 
the house-keeping enzyme Glyceraldehyde 3-phosphate 
dehydrogenase, GAPDH. It is specifically expressed in 
striated muscle and has important structural and signalling 
functions for the contractile units, sarcomeres. Each titin 
molecule spans half a sarcomere from the Z-disc to the 
M-band (Fig. 1). Decades of research have shed light on its 
functions, structure, binding partners and post-translational 
modifications, for reviews see e.g. Koser et al. (2019), Kru-
ger and Linke (2011), Lange et al. (2006), Zacharchenko 
et al. (2015). In this review, we will discuss the genetics 
of titin with respect to cardiac disease and how vertebrate 
animal and cellular models provide insight into the patho-
mechanisms related to titin variants. The equally important 
topic of the role of titin in skeletal muscle disease has been 
discussed elsewhere (Ottenheijm and Granzier 2010; Sava-
rese et al. 2016).
Identification of cardiomyopathy‑associated 
variants in titin
The enormous size of the human titin gene (TTN, 363 exons) 
makes it difficult, expensive and time-consuming to interro-
gate by conventional mutation screening approaches such as 
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Sanger sequencing. Additional complicating factors include 
(i) alternative splicing, generating various differentially 
expressed isoforms in tissues and (ii) that a large portion 
of TTN consists of repetitive tandem Immunoglobulin-like 
encoding sequences and that variants in these regions may 
have very little effect on TTN length and function (Greaser 
2009).
In 1999, the TTN locus (2q31) was associated with famil-
ial autosomal dominant dilated cardiomyopathy (DCM) for 
the first time (Siu et al. 1999). In the same year, Satoh and 
colleagues reported the first TTN single-base-pair missense 
variant in hypertrophic cardiomyopathy (HCM) (Satoh et al. 
1999).
Advancement of next-generation sequencing technologies 
in the last decades has made genetic analyses of TTN more 
accessible: it can now be interrogated as part of screening 
for the whole genome, the whole exome or targeted panel 
of genes in a rapid and cost-effective manner (Norton et al. 
2012). In a landmark study in 2012, Herman et al. conducted 
a genetic analysis of a large number of DCM, HCM and con-
trol cases and reported that TTN truncating variants (TTNtv, 
i.e. variants leading to a premature stop codon in TTN) are 
a common cause of DCM, occurring in approximately 25% 
of familial and 18% of sporadic cases, but only present in 
1% of HCM cases. Spatial distribution of variants found in 
HCM subjects and controls was distinct from that of DCM 
subjects. The DCM variants were predominantly located in 
the A-band region. This data has been integrated with RNA 
sequencing (RNAseq) data from diseased left ventricular 
samples to help understanding the role of TTNtv (Roberts 
et al. 2015). This study also determined the mean usage of 
each TTN exon, denoted as the proportion of transcripts that 
incorporate each exon (percentage spliced in, PSI) and they 
estimated that 50% of the TTNtv identified in healthy con-
trols occur in low PSI exons. Therefore, variants located in 
high PSI exons, including both N2BA and N2B isoforms, 
are strongly enriched in DCM patients versus controls. The 
penetrance of TTNtv in DCM appears to be strongly corre-
lated with its position; distal I-band and all A-band variants 
show larger odd ratios compared to very proximal or distal 
ones (Schafer et al. 2017).
TTNtv may cause the generation of short truncated TTN 
isoforms unable to span between the M-line and the Z-disc, 
or normal-sized TTN isoforms that attach poorly to the 
Z-disc (Neiva-Sousa et al. 2015). In either case, the presence 
Z-disc M-band Z-disc
I-band I-bandA-band
thick filamentthin filamenttitin
N
C
A-band titin = hotspot for DCM TTNtv
Fig. 1  Schematic drawing of the sarcomere. Each titin molecule 
(black) spans half the sarcomere from the Z-disc to the M-band, link-
ing thin filaments (bold black) and thick filaments (grey). The posi-
tions of I-band and A-band are also indicated. Bottom: The amino-
terminus (N) and the carboxy-terminus (C) of an individual titin 
molecule are marked (bottom of figure). The A-band portion of titin 
as a hotspot for DCM-causing variants is indicated. For more detailed 
schemes of titin domain structure please see Bang et  al. (2001), 
Lange et al. (2006)
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of abnormal TTN isoforms in the cardiomyocytes results in 
poorly contractile sarcomeres or may lead to DCM onset.
TTNtv have also be identified in the general population. 
From analyses of over 4500 control subjects TTNtv have 
been identified in 1.6% in individuals of African descent 
and 1.5% in individuals of European descent (Roberts et al. 
2015). Two different independent studies estimated that 3% 
of the population carries a TTNtv allele (Golbus et al. 2012; 
Herman et al. 2012). In a recent study, a similar frequency 
of TTNtv (~ 2%) was estimated in a cohort of Chinese HCM 
patients and one of healthy Chinese controls (Zhang et al. 
2017). This study showed for the first time that TTNtv 
increased the risk of cardiovascular death in patients with 
HCM and therefore they assigned a role to TTNtv in the 
phenotypic expression of the disease.
While the interpretation of TTNtv remains difficult 
due to the high frequency of these variants across normal 
populations and the lack of penetrance, the situation is far 
more complex for TTN missense variants, which have been 
identified in patients affected with different cardiac condi-
tions, such as DCM, HCM, arrhythmogenic cardiomyopathy, 
restrictive cardiomyopathy and left ventricular non-com-
paction cardiomyopathy (Arimura et al. 2009; Gerull et al. 
2002; Hastings et al. 2016; Itoh-Satoh et al. 2002; Matsu-
moto et al. 2005; Peled et al. 2014; Satoh et al. 1999; Taylor 
et al. 2011). However, it is likely that most of them act as 
‘benign’ variants and do not have a role in the development 
of disease (Begay et al. 2015). In support, a comprehensive 
study of 530 DCM patients found no enrichment of missense 
or in-frame small insertions/deletions in TTN when com-
pared to large population cohorts (Akinrinade et al. 2019). 
Nevertheless, for a rare subset of TTN missense variants, 
there is clear evidence for their role in the pathogenesis of 
cardiomyopathies, based on co-segregation studies in large 
families and in vivo disease models, e.g. Gerull et al. (2002), 
Hastings et al. (2016).
Although TTN plays a major role in the onset of DCM, 
due to its complexity, it is currently excluded from the list 
of genes to be reported as secondary findings by the Ameri-
can College of Medical Genetics (Kalia et al. 2017). When 
identified in patients, variants in TTN, especially missense 
ones, are often ignored in the first instance. To distinguish 
the rare disease-relevant variants from the majority of 
benign ones is a major, still unresolved challenge in clinical 
practice. Databases and bioinformatics tools are developed 
to help with the evaluation and interpretation of TTN vari-
ants (Table 1) and novel cellular model systems (see below) 
may help to address this issue experimentally in the future, 
as it has already been demonstrated for other cardiomyopa-
thy genes (Ma et al. 2018).
Insights into titin‑related cardiomyopathy 
studying human hearts
Given the scarcity of human cardiac tissue for research pur-
poses, especially from healthy control individuals, it is not 
surprising that only few studies have looked at molecular 
changes in the hearts of cardiomyopathy patients carrying 
titin variants (Roberts et al. 2015; Vikhorev et al. 2017). 
The main outcome of these studies is that no truncated titin 
proteins could be detected in individuals with TTNtv and 
that overall levels of titin transcript and protein are nor-
mal. Likewise, the isoform ratio N2B/N2BA is not altered. 
These findings argue against a haplo-insufficiency mode of 
action, yet support a dominant negative mode of action, but 
not through a poisonous-peptide mechanism. RNAseq data 
from 34 DCM patients with TTNtv identified alterations in 
mitochondrial function and fibrosis as molecular hallmarks 
of the disease (Verdonschot et al. 2018); however, these are 
unspecific features of many cardiomyopathies (Schirone 
et al. 2017).
Modelling titin variants in animal models
Whole organism models are valuable tools to study the con-
sequences of titin variants on the hearts. Important insights 
on titin function were gained from studying shorter titin-like 
proteins in invertebrates, such as twitchin in C. elegans and 
kettin in Drosophila; for reviews see Benian et al. (1999), 
Bullard et al. (2005), Ferrara et al. (2005). Zebrafish and 
mouse are the most commonly used animals to study cardiac 
functions of titin, but rat models and even a dog model also 
exist.
Table 1  Online resources to evaluate titin variants
Name Link References
Titin variants in dilated cardiomyopathy https ://www.cardi odb.org/titin / Roberts et al. (2015)
Leiden open variation database https ://datab ases.lovd.nl/share d/genes /TTN Fokkema et al. (2005)
Genome aggregation database https ://gnoma d.broad insti tute.org/gene/ENSG0 00001 55657 Karczewski et al. (2019)
Titindb http://frate rnali lab.kcl.ac.uk/TITIN db/ Laddach et al. (2017)
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Zebrafish models
Traditionally, zebrafish is a popular model organisms 
because of the ease of genetic modulation via random 
mutagenesis or morpholino oligomers, its short reproductive 
span and the transparent heart of its embryos, facilitating 
in vivo imaging (North and Zon 2003).
The pickwick mutant line is characterised by reduced 
contractility of its heart and poor myofibrillar maturation 
without mature sarcomeres (Xu et al. 2002), it is embryonic 
lethal. A homozygous single base pair change in the N2B 
region of titin, introducing a stop codon, was found to be 
the underlying genetic cause. It soon became apparent that 
there are two titin orthologs in zebrafish (ttna and ttnb) and 
that both the N2B-exon and N2A-exon containing isoforms 
of ttna are required for sarcomere assembly in the heart, 
while ttnb is dispensable for cardiac contractility (Seeley 
et al. 2007). An internal promotor, giving rise to the Cronos 
transcript, a C-terminal titin isoform, may explain why the 
position of truncation modulates disease severity, as was 
shown for skeletal muscle (Zou et al. 2015). However, there 
is still controversy about the evolutionary conversation and 
relevance of the Cronos transcript (Deo 2016; Shih et al. 
2016).
Moreover, the zebrafish model has provided insight into 
the increased risk of atrial fibrillation in individuals carry-
ing TTNtv (Ahlberg et al. 2018). A heterozygous TTNtv 
resulted in sarcomere defects in both ventricular and atrial 
chamber in the adult fish, as well as fibrosis and increased 
PR interval. These pathological changes may form a sub-
strate for atrial fibrillation.
Rodent and large animal models
Mice are by far the most established model organism to 
study gene function and its perturbation through genetic 
variants. As the global knock-out of titin is embryonic lethal 
(Radke et al. 2019), studies deleted important regions of the 
protein, such as the M-band portion (Gotthardt et al. 2003; 
Radke et al. 2019), the N2B region (Radke et al. 2007) and 
the PEVK region (Granzier et al. 2009), to understand the 
contributions of these regions to titin’s functions. All manip-
ulations lead to disturbances in cardiac function, however 
the exact phenotype (DCM, hypertrophy or atrophy) depends 
on the deleted region.
Gramlich et al. (2009) introduced the human DCM-caus-
ing TTNtv c. 43628insAT (Gerull et al. 2002) into a mouse 
model. In the homozygous setting the variant is embryonic 
lethal, while heterozygous mice have no overt phenotype. 
However, upon chronic challenge with angiotensin or upon 
pressure overload via trans-aortic constriction for 2 weeks, 
the heterozygous mice developed features of DCM, namely 
systolic dysfunction and dilatation, while wild-type mice 
undergoing the same treatment had preserved cardiac dimen-
sions and function. Also, TTNtv mice had increased lev-
els of fibrosis upon both challenges (Gramlich et al. 2009; 
Zhou et al. 2015). The angiotensin-induced phenotype of 
the mouse model could be rescued by antisense-mediated 
exon skipping, removing the premature stop from the tran-
script (Gramlich et al. 2015). Another successful therapeutic 
approach to improve cardiac function in these mice was inhi-
bition of miR-208b, a micro-RNA shown to be upregulated 
in the model (Zhou et al. 2017).
Rat models have been generated carrying TTNtv in either 
the Z-disc or the A-band portion of titin (Schafer et al. 
2017). Like their mouse counterparts, homozygous rats 
were not viable. Young heterozygous rats (< 8 months) have 
preserved cardiac function, but showed signs of concentric 
remodelling. In old rats (> 1 year), mild systolic dysfunction, 
not quite reaching statistical significance in all parameters, 
was observed, irrespective of the position of the variant. 
The main value of the models is that ribo-sequencing and 
RNAseq data revealed that TTN transcripts with an A-band 
TTNtv were transcribed and translated as far as the prema-
ture nonsense codon, where the translation stops; whereas 
the premature stop codon of the TTNtv in the Z-disc did 
not prevent translation downstream. Regardless the position 
of the variant within the protein, TTNtv lead to nonsense-
mediated degradation of the mutant allele and a signature 
of perturbed cardiac metabolism but they result in different 
translational footprints (Schafer et al. 2017).
A further study subjected the rat model with the TTNtv at 
the Z-disc to pressure overload by trans-aortic constriction. 
This resulted in mild diastolic dysfunction, increased fibrosis 
and reduced capillary density. Additionally, more apopto-
sis was observed in these mice (Ye et al. 2018). Finally, a 
more detailed molecular analysis of both rat models revealed 
impaired autophagy and mitochondrial defects leading to 
reactive oxygen species production and increased acetyla-
tion of mitochondrial proteins as disease mechanisms (Zhou 
et al. 2019). The study further demonstrated that mTOR 
inhibitor rapamycin can rescue the autophagy defects in 
these rat models, leading to the speculation that this could 
be an intervention to ameliorate ventricular remodelling 
associated with TTNtv.
Furthermore, a dog model of titin missense variant exists 
(Meurs et al. 2019), this homozygous or heterozygous mis-
sense change in immunoglobulin domain I71 in the N2BA 
isoform was identified in a Doberman pinscher dog pedigree 
with familial DCM and a high incidence of sudden cardiac 
death.
Journal of Muscle Research and Cell Motility 
1 3
Modelling titin variants in induced 
pluripotent stem cell derived 
cardiomyocytes
Major cellular reprogramming breakthroughs now allow the 
reversal of terminally differentiated human cells (e.g. fore-
skin or skin fibroblasts, white blood cells) into pluripotency 
using reprogramming factors (Oct4, Sox2, Klf4, and c-myc) 
(Takahashi and Yamanaka 2006). Directed differentiation of 
human-induced pluripotent stem cells (iPSCs) into cardio-
myocytes (iPSC-CMs) can be achieved by manipulation of 
Wnt signalling (Lian et al. 2012). iPSC-CMs can provide a 
long-term human in vitro model to investigate titin variants 
and their role in cardiomyopathy; they have the potential to 
mimic human pathophysiology as they are not affected by 
species-related physiological differences (such as heart rate 
and ion channel setup) between humans and rodents. How-
ever, foetal characteristics and immaturity are major draw-
backs of iPSC-CMs, for review of this subject see Jiang et al. 
(2018), Yang et al. (2014). Tissue engineering techniques 
such as cardiac microtissue, engineered heart tissue and 
engineered human myocardium are 3D culturing techniques 
that enable more mature phenotypes of iPSC-CMs, e.g. in 
respect to sarcomere organisation (Giacomelli et al. 2017; 
Hansen et al. 2010; Tiburcy et al. 2017). Alternatively, nano-
patterning on substrates of physiological stiffness (Ribeiro 
et al. 2015), scaffolds (Blazeski et al. 2019) or bioactive 
lipids (Sharma et al. 2018) have been shown to improve 
iPSC-CM maturation. However, iPSC-CM are unlikely to 
reach full characteristics of adult cardiomyocytes morpho-
logically or physiologically (Fig. 2).
iPSC-CMs are particularly powerful when combined 
with genome-editing techniques such as Clustered regularly 
interspaced short palindromic repeat (CRISPR)/CRISPR-
associated protein 9 (Cas9) or Transcription activator-like 
effector nucleases (Chen et al. 2015; Ding et al. 2013). 
In principle, there are two approaches to study the conse-
quences of variants e.g. in titin: patient-derived iPSC-CMs 
carrying the disease-associated variant are compared to 
iPSC-CMs from healthy control individuals (ideally close, 
unaffected family members) and/or an iPSC line in which the 
disease-associated variant is reverted to the wildtype allele 
via genome-editing. An alternative approach is to introduce 
a disease-associated variant into iPSC derived from a normal 
individual and using isogenic un-edited or control-edited 
iPSC as controls. The advantage of the latter approach is 
that both hetero- and homozygous variants can be generated. 
Examples of both approaches will now be discussed:
iPSC-CMs derived from DCM patients carrying A-band 
TTNtv (Ser14450fsX and Ser19628IfsX) exhibited a marked 
reduction in contraction amplitude, alterations in calcium 
transients and sarcomeric structural disruption, with less 
iPSC-CM displaying fully organised sarcomeres compared 
to iPSC-CM from a healthy control individual (Gram-
lich et al. 2015; Schick et al. 2018). Rescue by skipping 
the affected exon with antisense oligonucleotides resulted 
in improved myofibril assembly and stability as well as in 
a normalised gene expression profile, similar to the func-
tional rescue observed in a corresponding mouse model (see 
above) (Gramlich et al. 2015).
Hinson et al. (2015) carried out an investigation into the 
penetrance of two TTNtv (Ala22352fsX and Pro22582fsX) 
and one missense variant (Trp976Arg) in the A-band and 
Z/I-band junction of the sarcomere respectively using both 
patient-derived iPSC-CMs and genome-edited iPSC-CMs, 
both in 2D cultures and cardiac microtissue. Both TTNtv 
lines displayed significant reductions in contractile forces 
compared to wildtype iPSC-CMs although I-band TTNtv 
did not result in the same pronounced pathogenic pheno-
types inferring a reduced penetrance (Hinson et al. 2015). A 
further study of an A-band TTNtv showed that the resultant 
shortened titin also displayed impaired contractile perfor-
mance, poor sarcomere assembly and myosin mechanical 
force (Chopra et al. 2018).
Taken together, the small number of studies of DCM-
associated titin variants in iPSC-CMs so far have revealed 
reduced contractility and impaired sarcomere assembly as 
contributors to the disease.
iPSC-CM:
nano-patterned
adult mouse
cardiomyocyte
iPSC-CM: glass iPSC-CM: hydrogel
Fig. 2  Immature phenotype of iPSC-CM in conventional 2D cul-
tures: Normal Kolf2 iPSC (Streeter et  al. 2017) were differenti-
ated into iPSC-CMs using standard methods (Burridge et  al. 2015) 
and plated on day 20 on different substrates: matrigel coated glass 
(top left), matrigel coated hydrogel (top right, 7  kPa) and nano-
patterned matrigel coated hydrogel (bottom left, see Ribeiro et  al. 
(2015)).  30  days after induction of differentiation, cells were fixed 
and sarcomeric structures visualised with an antibody direct against 
alpha-actinin (EA53, Sigma). For comparison, an isolated mouse car-
diomyocyte stained with the same antibody is shown (bottom right). 
Scale bars represent 10 microns
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New methodological developments: 
opportunities to advance the use of iPSC‑CM 
for studying titin variants
Functional assessment of contractility is still an issue in 
iPSC-CM, as established methods used for adult mouse car-
diomyocytes, which track changes of the visible striation 
of highly organised sarcomeres, fail in the less organised 
iPSC-CM. However, recent advancements of open-source 
contractility analysis software tools such as MuscleMotion 
and SarcTrack will help to shed light on the role of titin 
variants in cardiac contractility: MuscleMotion is an ImageJ 
plug-in allowing the label-free quantification of contraction 
of e.g. individual iPSC-CMs, 2D monolayers or engineered 
heart tissue based on analysing changes in pixel intensity rel-
ative to a reference frame (Sala et al. 2018). SarckTrack is a 
recent MatLab contractility software which allows hundreds 
of individual fluorescently-labelled sarcomeres in iPSC-CM 
to be analysed in each cell (Toepfer et al. 2019).
Moreover, recent diversifications of the CRISPR/Cas9 
toolbox open new avenues to manipulate iPSC-CMs: its 
traditional application is in genome-editing, utilising non-
homologous end joining or homologous directed repair 
(reviewed in Devkota (2018), Singh et  al. (2017)). The 
former is commonly used to generate null alleles via small 
insertion/deletion disrupting the reading frame (Chopra et al. 
2018), the latter is used to introduce fusion tags e.g. a green 
fluorescent protein titin fusion to visualise sarcomeres (Toe-
pfer et al. 2019) or site-specific variants, e.g. TTNtv (Hinson 
et al. 2015).
The specificity of CRISPR is also captured as a site-
specific molecular localiser. Different functional molecules 
can be tethered with catalytically deficient Cas9 (dCas9) 
and guided to the target locus without genetic perturbation 
(Knott and Doudna 2018; Larson et al. 2013). Firstly, the 
CRISPR activation system (CRISPRa) recruits positive tran-
scription regulators to the promoter or proximal enhancer 
regions and thereby drives gene expression (Hilton et al. 
2015; Konermann et al. 2015; Zhang et al. 2015). This tech-
nology wins over the conventional overexpression systems, 
which depend on a random integration of the expression 
vectors, as it does not affect the host’s DNA sequence. Vari-
ous modified versions of this gene regulation tool have been 
developed to include different effectors, or in combination, 
to maximise the fold activation (Chavez et al. 2016; Hilton 
et al. 2015). Modelling disease systems with distinguished 
expression profiles and governing key transcription factor 
expression to direct differentiation (Weltner et al. 2018) are 
promising applications of CRISPRa.
On the contrary, CRISPR interference (CRISPRi), blocks 
transcriptional activity by a steric hindrance between dCas9 
and the transcriptional machinery (Larson et al. 2013) or by 
the actions of tethered transcription repressors (Parsi et al. 
2017). Compared to existing gene knockdown methods 
owing to various advantages: CRISPRi is more effective in 
gene silencing as it acts directly at the transcriptional status, 
while RNA interference modulates the expression at mRNA 
level (Agrawal et al. 2003). Moreover, RNA interference 
targets are limited to cytosolic mRNAs but CRISPRi holds 
a broader target repertoire, including coding and non-coding 
sequences (Gilbert et al. 2014). The modularity of CRISPR 
system makes it easy to create guide RNA libraries. Lastly, 
the repression activity can be fine-tuned by changing the 
target region or by probing multiple sites simultaneously—
CRISPRi can even be switched on or off using inducible 
CRISPRi-KRAB (Parsi et al. 2017) if time-dependent study 
is needed for example to dissect developmental phases.
In summary, the CRISPR/Cas9 system provides exciting 
tools beyond conventional genome-editing to study e.g. the 
consequences of titin variants in the cardiac system.
Conclusion
While a causal role for TTNtv in DCM is now well estab-
lished, the underlying disease pathways are still not fully 
understood. Animal models have highlighted a crucial role 
of titin for the integrity of the heart and have helped to gain 
insight into aspects of titin’s function, such as sarcomere 
assembly and signalling and their perturbations by titin vari-
ants. However, animal models are limited by species-related 
differences in morphology and physiology to humans. As 
an alternative, studies of human cardiac tissue can also pro-
vide insights into the patho-mechanisms of titin variants, 
but such tissue is rarely available in sufficient quality and 
quantity. Therefore iPSC-CM emerge as a novel model sys-
tem to study titin-related cardiomyopathy. These cells allow 
mimicking human genetic disease in a human cardiac cel-
lular model. While still in its infancy and currently plagued 
by the issue of immaturity, it provides exciting approaches 
to study the role of titin variants in cardiomyopathies and 
we are looking forward to future developments in the field.
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